Royalty Report: Drugs, Drug Discovery, Cancer – Collection: 324682

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • Drug Discovery
  • Cancer
  • Antibody
  • Respiratory
  • Therapeutic
  • Vaccine
  • DNA
  • Assay
  • ribonucleic acid
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 324682

License Grant
The Licensor of the United Kingdom grants to the Licensee of the United Kingdom a license under the Licensed Technology to
–  undertake research with a view to Developing Licensed Products and Combination Products for use in the Field;
–  Develop and have Developed Licensed Products and Combination Products for use in the Field;
–  apply for, obtain and maintain Regulatory Approvals (other than Marketing Authorizations) for Licensed Products and Combination Products for use in the Field;
–  Manufacture, have Manufactured and otherwise make and have made, use and have used Licensed Products and Combination Products for use in the Field;
–  apply for, obtain and maintain Marketing Authorizations for Licensed Products and Combination Products in the Field in the Territory; and
–  Market Licensed Products and Combination Products in the Field in the Territory.

Portions of this license are exclusive, and others are co-exclusive with Licensor.

License Property
The patent is entitled Method for generating a memory T-cell response.

Licensed Product means any form or dosage of pharmaceutical composition or preparation for use in humans which is intended to prevent or treat Mycobacterium tuberculosis but no other disease and which contains
(a) a recombinant replication-impaired or non-replicating MVA, containing heterologous nucleotide sequence encoding all or an immunogenic fragment or fusion protein of antigen 85A of Mycobacterium tuberculosis and no other non-MVA expressed gene (aside from a marker gene); or
(b) a Multivalent TB Product.

Licensed Technology means all Intellectual Property Rights Controlled by the Company in
(a) the Company Patent Rights;
(b) the Company Know-how;
(c) the Master Seed Stock;
(d) Company Seed Stock;
(e) Company Manufacturing Technology;
(f) Emergent ODP Technology; and
(g) the Documents

Multivalent TB Product means a recombinant replication-impaired or non-replicating MVA containing a heterologous nucleotide sequence encoding all or an immunogenic fragment or fusion protein of antigen SSA of Mycobacterium tuberculosis and any promoter or leader nucleotide sequences required for expression of that antigen; and one or more of the following (whether co-formulated or co-administered with such viral vector)
(a) one or more heterologous nucleotide sequences encoding all or an immunogenic fragment or fusion protein of an antigen or antigens, other than SSA, of Mycobactenum tuberculosis and any promoter or leader nucleotide sequences required for expression of that antigen and no antigens (other than MVA antigens and a marker, if present) from any other pathogen;
(b) one or more full length protein(s) or immunogenic fragment(s) or fusion protein(s), of a Mycobacterium tuberculosis antigen or antigens (and including l1poproteins, glycoproteins polysaccharides and protein -polysaccharide conjugates) other than antigen SSA;
(c) an additional vector system for the expression of Mycobactenum tuberculosis antigens, enabling expression within viral, prokaryotic and/or eukaryotic cells;
(d) a delivery system for Mycobacterium tuberculosis antigens including Bacterial RNA capsids, microparticles, vesicles and liposomes.

MVA means modified vaccinia virus Ankara.

MVABSA means a recombinant replication-impaired or non-replicating MVA, containing heterologous nucleotide sequence expressing all or an immunogenic fragment or fusion protein of a major secreted antigen from Mycobacterium tuberculosis, antigen SSA, and no other non-MVA expressed gene (aside from a marker gene), and known as the MVASSA vaccine and described in the Patent Application.

Field of Use
The field of use is the Prevention and treatment of Mycobacterium tuberculosis disease (and only Mycobacterium tuberculosis disease) in humans; provided that with respect to a Combination Product, the Field shalI also include such other indications as a retreated or prevented by the Other Product.

Mycobacterium tuberculosis is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis.  Tuberculosis generally affects the lungs, but can also affect other parts of the body.

IPSCIO Record ID: 294014

License Grant
Licensor, a medical research centers, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
The patents and patent applications relate to Modified Adena-Associated Virus Vector Capable of Expression from a Novel Promoter.

Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

Field of Use
The field of use is the development of compositions and methods utilizing Adeno-Associated Viral Vectors embodied in the Licensed Patent Rights which are useful in the treatment and prophylaxis of human and animal diseases, and does not include compositions and methods for the treatment and prophylaxis of cystic fibrosis.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 336310

License Grant
The Canadian University grants an exclusive license in all jurisdictions of the world to the Licensed Technology for the purpose of developing, producing, exploiting, using, selling or otherwise commercially exploiting, or having developed, produced, used, sold or otherwise commercially exploited, the Licensed Technology for use in non-humans, and for use in technology relating to the GDF-8 protein in both humans and non-humans but specifically excluding use of the Licensed Technology in vaccines to prevent infectious diseases.

For greater particularity and notwithstanding the foregoing, this license is non-exclusive as to its use for diagnostic applications for Pasteurella haemolytica or Bovine Herpes Virus-1 antibodies.

License Property
Licensed Technology means the Adjuvant Technology and proteins, peptides, nucleic acids, antibodies and adjuvants and methods of production and uses described in the Licensed Patents referenced including the use of Pasteurella haemolytica or Bovine Herpes Virus-1 antigens as immunological carriers, including products based upon leukotoxin carrier, GnRh or vasoactive intestinal peptide, and further includes all provisional applications, know-how, proprietary technical data, information, biological materials and reagents useful in  working with the subject matter of the Licensed Patents.

Licensed Patents include Adjuvant Formulation with Enhanced Immunogenic Activity, and Related Compositions and Methods; Nucleotide Sequences Encoding Recombinant Bovine Herpesvirus Type 1, gl, gill, gIV Polypeptides; Bovine Herpesvirus Type 1 Polypeptides and Vaccines;  Compositions and Treatments for Pneumonia in Animals, and other related patents.

Myostatin Product means a Product that comprises myostatin also known as growth differentiating factor 8 (GDF-8) protein, peptide or nucleic acid.

Field of Use
The field is for use in non-humans, and for use in technology relating to the GDF-8 protein in both humans and non-humans.

IPSCIO Record ID: 230788

License Grant
Licensor grants an exclusive license in the Territory, including the right to grant sublicenses, to manufacture, use, sell, offer for sale, and import Products under all its right, title and interest in the Patent Rights.
License Property
Product means any animal vaccine or therapeutic agent the manufacture, use, sale, offer for sale or import of which would infringe any Valid Claim within Patent Rights in the absence of a license.

Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.

The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS  phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.

Field of Use
The field of use Area means research, development and commercialization with respect to animal vaccines and therapeutic agent as further described in the Research Plan.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 372444

License Grant
The existing agreement is for the rights to use Licensor’s antibody phage display technology.  This agreement is to extend the term  and amend other terms.

Licensee shall have rights to use and practice the Licensor Technology, and Licensor licensed Patent Rights and Know-How as follows
— For the Licensor Antibody library, Licensor grants to Licensee a world-wide, nonexclusive license, without the right to grant sublicenses, to use the Licensor Antibody Library and to practice the Licensor Patent Rights solely in connection with the use of the Licensor Antibody Library to research, develop and make Antibody Compounds and a world-wide, nonexclusive license, with the right to sublicense, to use the Antibody Compounds in order to make, have made, use, sell or import Licensed Products.

For Licensor Materials, In connection with the practice of the license rights set forth, Licensor grants to Licensee a worldwide, non-exclusive, non-transferable license, without the right to grant sublicenses, to use the Licensor Materials on its own behalf only to identify Antibody Compounds from the Licensor Antibody Library and to make quantities of Antibody Compounds that are reasonably required for research and development activities only.

For the Third Party Sublicense Rights, During the library License Term, Licensee shall have rights to use and practice the Licensor licensed Patent Rights and Know-How.

License Property
Licensor possesses intellectual property and know-how related to, among other things, the discovery of antibodies having novel binding properties using phage display.

Licensed Product means any Antibody Compound or product that incorporates an Antibody Compound, whether or not conjugated to another compound that is a Therapeutic Product or an In Vitro Diagnostic Product.

The licensed library is The phagemid-based Fab library.

Licensed materials include Expression vectors pXPlsacB and pXP2sacB for soluble Fab production in E. coli. IgG expression vectors (pBRV and pShuttle) for rapid subclomng and converting Fab fragments into human IgGl and IgG4 and munne IgG2a. (Streptavidin-binding antibody clones will be provided as a positive control.)

The patents include
— Phage display patents
— Focused libraries of genetic packages
— Novel methods of constricting libraries of human FAB antibody fragments displayed on filamentous phage
— Ligand Screening and Discovery
— Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
— Novel Plasmid Vector with Pectate Lyase Signal Sequence

Field of Use
The field of use is Therapeutic Field of Use means shall mean human therapeutics only and not for any in vitro or in vivo diagnostics, purification or separations, research products nor for any other purposes.

IPSCIO Record ID: 369334

License Grant
Licensor of England grants a world-wide non-exclusive license under the Intellectual Property to exploit the System make, have made, use, develop, manufacture, market, sell, have sold, offer for sale, distribute, import, and export Product in the Territory.
License Property
The Product means a humanized monoclonal antibody known as Sphingomabâ„¢, which targets sphingosine-1-phosphate (S1P), or an S1P-binding fragment thereof, of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System.

The System means Licensors glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination with each other.

Field of Use
Licensee has announced the humanization of its Sphingomabâ„¢ monoclonal antibody against sphingosine-1-phosphate (S1P). S1P is an important bioactive lipid that has been well validated as a cancer drug target.

IPSCIO Record ID: 372515

License Grant
Licensor of England grants to Licensee of Canada, an exclusive, worldwide license under the Licensed Patents to develop, make, have made, possess, utilize, sell, have sold and otherwise exploit the Licensed Products in the Territory.
License Property
Licensor is the owner of an invention, made at Licensor, relating to polymorphic epithelial mucin peptide in respect of which Licensor has made certain patent applications.

The New MUC1 Invention means any invention related and pertaining to
— MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof; and
— methods of making and using any MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof for the detection, evaluation, prevention and/or treatment of cancer.

Peptide means any peptide, polypeptide or protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof which is covered by a Valid Claim of the Licensed Patents.

Field of Use
The Field means the treatment or diagnosis of cancer.

IPSCIO Record ID: 256276

License Grant
The Licensor of England grants to Licensee of Germany a nonexclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Field.
License Property
Licensor is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development.

Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.

The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.

Field of Use
The Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the Target. Target means the whole or part and natural variants of the granulocyte-macrophage colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession number P04141 with the amino acid sequence which is specifically recognized by an Antibody binding to the foregoing.

Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.

IPSCIO Record ID: 372419

License Grant
This amendment 4 expands the field.  The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases and vaccines, and Licensee now agree to further modify the scope of the Agreement to include new patent families and expand the field to include all therapeutic applications in the Field.
License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature.  The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.

Field of Use
The Field shall mean Gene therapy for the treatment and prevention of human disorders, including, without limitation, the use of chimeric antigen receptor T-cells.

Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.

IPSCIO Record ID: 372469

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
—  exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
—  non exclusive for Products containing non-human lentivirus vector.
License Property
Licensor has identified and patented a specific nucleotide sequence having a triplex structure, referred to as DNA flap, covered by patents and patent applications.

Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.

Field of Use
Field shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALO) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to betathalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease; for Parkinsons Disease and eye diseases (including but not limited to AMD and Stargardt disease)].  The Field includes in vivo as well as ex vivo gene therapy.

IPSCIO Record ID: 230760

License Grant
Licensor grants the exclusive license, under the Licensor Patents, the Licensor Know-How and Licensors interest in any Joint Technology; and,  the exclusive sublicense, under Licensors rights under a Materials Transfer and Intellectual Property Agreement, in each case solely to manufacture, to the extent set forth in the Supply Agreement, develop, distribute, use, import, offer for sale and sell the Product in the Territory for use in the Field during the Co-Promotion Term.

Licensor grants the right to distribute Product through its Affiliates or Third Party distributors in the Territory, but in any event only through distributors performing usual and customary distribution activities for Licensee, to the extent that Licensee itself otherwise has the right to so distribute such Product in the Territory for use in the Field during the Co-Promotion Term, provided that Licensee may not grant any such distributor a sublicense hereunder to offer for sale or sell, or repackage, re-import or export the Product.

License Property
Licensor has an intranasally delivered cold adapted vaccine formulation against influenza and influenza-associated illnesses, including otitis media infection, known as FluMist(TM).  The primary brand trademark means FluMist(TM) and FluEnz(TM), as well as any brand names combining FluMist or FluEnz with other words, e.g. Pediatric FluMist.

The product means Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains, including, but not limited to, the Frozen Formulation and the Liquid Formulation; provided, however, that Product specifically excludes any other Formulation or mode of delivery other than intranasal spray unless and until such Other Formulation or mode of delivery has been included under the Collaboration.  Product also specifically excludes any influenza vaccine Controlled by Licensor which is solely based upon or derived from strains other than the Master Donor Strains and their derivatives or other technologies of Licensor;  any product comprising Licensors live, attenuated, intranasally delivered, cold adapted influenza vaccine derived from the Master Donor Strains in combination with any other vaccine or vaccines; and, any product in which a viral vector derived from the Master Donor Strains is used to deliver a vaccine or other heterologous gene sequence for use in the prevention, mitigation or cure of influenza.

Field of Use
Field means the use of the Product pursuant to a physicians direct or standing prescription to prevent influenza and influenza-associated illnesses including otitis media infection in a Target Population, or other population, for which the Product is approved by the FDA; or, for any other indication which are specifically included under the Collaboration.  The Field specifically excludes use or sale of the Product in the OTC Market.

IPSCIO Record ID: 372551

License Grant
For the Grant of Licensee Product License by Licensor of the United Kingdom To Licensee, In the event Licensor notifies Licensee above that a Nominated Target has passed the Licensor Gatekeeping Procedure, then upon receipt by Licensor of the applicable Acceptance Fee, Licensor agrees to grant and hereby grants to a non-exclusive license, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory, the Licensee Product License.

For the Grant of Other Licenses for Other Products, Licensor grants with effect from 3 January 2003 to Licensee a non-exclusive license in the Territory, with the right to sublicense, under the Licensor Antibody Phage Display Patents and the Licensor Know How for any purpose not already covered by the provisions of this Agreement, Other Purposes, including to Exploit any product, other than a Therapeutic Antibody Product, Diagnostic Antibody Product or Research Product, whose development, manufacture, use or sale would, absent the license hereunder, infringe Valid Claims of the Licensor Antibody Phage Display Patents or utilize the Licensor Know-How, Other Product License.

License Property
Licensor is the owner or exclusive licensee of the Licensor Antibody Phage Display Patents.

Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

Licensor Product means any preparation for the treatment or prevention of disease, infection, or other condition in humans for any indication which contains, comprises, or the process of development or manufacture of which utilizes a Licensee Licensable Antibody, or, any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction, or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensee Licensable Antibody.

Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody.

Target shall mean
— a polynucleotide sequence corresponding to a sequence identified in a publicly available curated
database such as GenBank® by means of an accession number or similar sequence information
that uniquely identifies that sequence;
— a non-proteinaceous antigen that is uniquely identifiable in a routine manner using publicly
available curated databases and/or such other suitable written material as is available.

The Licensor Know-How includes
— Training Manual 'Antibody Phage Display' 2002.
— mammalian expression IgG vectors
—-pEU1 .2 (human gamma-1 heavy chain)
—-pEU3.2 (human kappa light chain)
—-pEU4.2 (human lambda light chain), and,
—-pEU8.2 (human gamma-4 heavy chain).

Field of Use
Antibody phage display is a versatile, in vitro selection technology that can be utilized to discover high affinity antibodies specific to a wide variety of antigens (94).

The Field of Use means research and development of human or non-human therapeutics and human or nonhuman in vitro diagnostic or research reagent uses only and not any in vivo diagnostics, purifications or separations, or other industrial purposes.

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.